Literature DB >> 7618280

High-level expression of the measles virus nucleocapsid protein by using a replication-deficient adenovirus vector: induction of an MHC-1-restricted CTL response and protection in a murine model.

A R Fooks1, E Schadeck, U G Liebert, A B Dowsett, B K Rima, M Steward, J R Stephenson, G W Wilkinson.   

Abstract

Replication-deficient adenovirus (Ad) vectors provide an efficient technology for direct DNA delivery to cells both in vitro and in vivo. We have inserted the measles virus nucleoprotein (N) gene under the control of the strong constitutive CMV major IE promoter into an Ad type 5 E1- vector to produce the recombinant virus RAd68. Following infection of human fibroblasts with RAd68 in vitro, recombinant N protein was synthesized as a 60-kDa protein that represented up to 20% total soluble cell protein. Long filamentous structures were produced in both the nucleus and the cytoplasm that were similar in appearance to measles virus nucleocapsids. These "nucleocapsid-like" structures were readily purified by density gradient centrifugation. Murine immunization with RAd68 elicited (i) a humoral immune response to N, (ii) a major histocompatibility complex class I-restricted, antigen-specific cytotoxic T cell response, and (iii) protection against challenge with the measles virus CAM/RB strain in mice. This study demonstrates the capacity of replication-deficient Ad recombinants both to induce and to characterize cell-mediated immune responses.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7618280     DOI: 10.1006/viro.1995.1362

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  21 in total

1.  Gene delivery into neuronal and glial cells by using a replication-deficient adenovirus vector: prospects for neurological gene therapy.

Authors:  S Sivasubramaniam; A Fooks; J Lee; G Stacey; A Jennings
Journal:  Cytotechnology       Date:  1997-09       Impact factor: 2.058

Review 2.  Avian influenza pandemic preparedness: developing prepandemic and pandemic vaccines against a moving target.

Authors:  Neetu Singh; Aseem Pandey; Suresh K Mittal
Journal:  Expert Rev Mol Med       Date:  2010-04-29       Impact factor: 5.600

3.  New pre-pandemic influenza vaccines: an egg- and adjuvant-independent human adenoviral vector strategy induces long-lasting protective immune responses in mice.

Authors:  M A Hoelscher; L Jayashankar; S Garg; V Veguilla; X Lu; N Singh; J M Katz; S K Mittal; S Sambhara
Journal:  Clin Pharmacol Ther       Date:  2007-10-24       Impact factor: 6.875

4.  Characterization of adenovirus hexons by their epitope composition.

Authors:  E Adám; I Nász; A Lengyel
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

Review 5.  Drug delivery issues in vaccine development.

Authors:  M F Powell
Journal:  Pharm Res       Date:  1996-12       Impact factor: 4.200

6.  Recognition of the measles virus nucleocapsid as a mechanism of IRF-3 activation.

Authors:  Benjamin R tenOever; Marc J Servant; Nathalie Grandvaux; Rongtuan Lin; John Hiscott
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

7.  Neutralizing human Fab fragments against measles virus recovered by phage display.

Authors:  Cristina de Carvalho Nicacio; R Anthony Williamson; Paul W H I Parren; Ake Lundkvist; Dennis R Burton; Ewa Björling
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

8.  A recombinant adenovirus expressing an Epstein-Barr virus (EBV) target antigen can selectively reactivate rare components of EBV cytotoxic T-lymphocyte memory in vitro.

Authors:  S M Morgan; G W Wilkinson; E Floettmann; N Blake; A B Rickinson
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

9.  Adenovirus vector delivery stimulates natural killer cell recognition.

Authors:  Peter Tomasec; Eddie C Y Wang; Veronika Groh; Thomas Spies; Brian P McSharry; Rebecca J Aicheler; Richard J Stanton; Gavin W G Wilkinson
Journal:  J Gen Virol       Date:  2007-04       Impact factor: 3.891

10.  Characterization of the Ebola virus nucleoprotein-RNA complex.

Authors:  Takeshi Noda; Kyoji Hagiwara; Hiroshi Sagara; Yoshihiro Kawaoka
Journal:  J Gen Virol       Date:  2010-02-17       Impact factor: 3.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.